These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38572639)

  • 1. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
    Waxman AB; Systrom DM; Manimaran S; de Oliveira Pena J; Lu J; Rischard FP
    Circ Heart Fail; 2024 May; 17(5):e011227. PubMed ID: 38572639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary vascular and right ventricular reserve in patients with normalized resting hemodynamics after pulmonary endarterectomy.
    Claessen G; La Gerche A; Dymarkowski S; Claus P; Delcroix M; Heidbuchel H
    J Am Heart Assoc; 2015 Mar; 4(3):e001602. PubMed ID: 25801760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.
    Elinoff JM; Rame JE; Forfia PR; Hall MK; Sun J; Gharib AM; Abd-Elmoniem K; Graninger G; Harper B; Danner RL; Solomon MA
    Trials; 2013 Apr; 14():91. PubMed ID: 23547564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exercise Capacity and Ventilatory Efficiency in Patients With Pulmonary Arterial Hypertension.
    Tobita K; Goda A; Teruya K; Nishida Y; Takeuchi K; Kikuchi H; Inami T; Kohno T; Tashiro S; Yamada S; Satoh T; Soejima K
    J Am Heart Assoc; 2023 Jun; 12(11):e026890. PubMed ID: 37260024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial.
    Ehlken N; Lichtblau M; Klose H; Weidenhammer J; Fischer C; Nechwatal R; Uiker S; Halank M; Olsson K; Seeger W; Gall H; Rosenkranz S; Wilkens H; Mertens D; Seyfarth HJ; Opitz C; Ulrich S; Egenlauf B; Grünig E
    Eur Heart J; 2016 Jan; 37(1):35-44. PubMed ID: 26231884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
    Surie S; Reesink HJ; Marcus JT; van der Plas MN; Kloek JJ; Vonk-Noordegraaf A; Bresser P
    Clin Cardiol; 2013 Nov; 36(11):698-703. PubMed ID: 24037998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
    Souza R; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Lin J; Johnson-Levonas AO; de Oliveira Pena J; Humbert M; Hoeper MM
    Eur Respir J; 2023 Sep; 62(3):. PubMed ID: 37696565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Mobile Health Intervention to Increase Physical Activity in Pulmonary Arterial Hypertension.
    Hemnes AR; Silverman-Lloyd LG; Huang S; MacKinnon G; Annis J; Whitmore CS; Mallugari R; Oggs RN; Hekmat R; Shan R; Huynh PP; Yu C; Martin SS; Blaha MJ; Brittain EL
    Chest; 2021 Sep; 160(3):1042-1052. PubMed ID: 33878341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment goals of pulmonary hypertension.
    McLaughlin VV; Gaine SP; Howard LS; Leuchte HH; Mathier MA; Mehta S; Palazzini M; Park MH; Tapson VF; Sitbon O
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D73-81. PubMed ID: 24355644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study.
    Peacock AJ; Crawley S; McLure L; Blyth KG; Vizza CD; Poscia R; Francone M; Iacucci I; Olschewski H; Kovacs G; Vonk Noordegraaf A; Marcus JT; van de Veerdonk MC; Oosterveer FP
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):107-14. PubMed ID: 24173272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension.
    Vonk Noordegraaf A; Channick R; Cottreel E; Kiely DG; Marcus JT; Martin N; Moiseeva O; Peacock A; Swift AJ; Tawakol A; Torbicki A; Rosenkranz S; Galiè N
    JACC Cardiovasc Imaging; 2022 Feb; 15(2):240-253. PubMed ID: 34801462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic Resonance-Augmented Cardiopulmonary Exercise Testing: Comprehensively Assessing Exercise Intolerance in Children With Cardiovascular Disease.
    Barber NJ; Ako EO; Kowalik GT; Cheang MH; Pandya B; Steeden JA; Moledina S; Muthurangu V
    Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27940957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.